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Introduction: Multimodality therapy, including preoperative chemoradiotherapy (CRT) and total mesorectal excision
(TME), has effectively reduced local recurrence rates of rectal cancer over the past decade. However, the benefits
and risks of the addition of neoadjuvant CRT to surgery need to be evaluated. This study was to compare the
efficacy of TME with versus without preoperative concurrent chemoradiotherapy (CCRT) involving XELOX regimen
(oxaliplatin plus capecitabine) in Chinese patients with stages II and III mid/low rectal adenocarcinoma.
Methods: We randomly assigned patients to the TME group (TME without preoperative CCRT) or CCRT + TME
group (TME with preoperative CCRT). The primary endpoint was disease-free survival (DFS); the secondary endpoints
were overall survival (OS), local and distant recurrence, tumor response to CRT, toxicity, sphincter preservation, and
surgical complications. An interim analysis of the potential inferiority of DFS in the CCRT + TME group was planned
when the first 180 patients had been followed up for at least 6 months.
Results: A total of 94 patients in the TME group and 90 patients in the CCRT + TME group were able to be
evaluated. The 3-year DFS and OS rates were 86.3 % and 91.5 % in the whole cohort, respectively. The 3-year DFS
rates of the TME and CCRT + TME groups were 85.7% and 87.9 % (P = 0.766), respectively, and the 3-year OS rates
were 90.7 % and 92.3 % (P = 0.855), respectively. The functional sphincter preservation rates of the TME and CCRT +
TME groups were 71.3 % and 70.0 % (P = 0.849), respectively. In the TME group, 16 (17.0 %) patients were proven to
have pTNM stage I disease after surgery. In the CCRT + TME group, 32 (35.6 %) patients achieved a pathologic
complete response (pCR).
Conclusions: Preliminary results indicated no significant differences in the DFS, OS, or functional sphincter
preservation rates between the TME and CCRT + TME groups. However, preoperative CCRT with XELOX yielded a high
pCR rate. Newer techniques are needed to improve the staging accuracy, and further investigation is warranted.
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In China, colorectal cancer is the fifth most common can-
cer in male and the third most common cancer in female
[1]. In 2014, 40,000 new cases of rectal cancer (23,380
male cases and 16,620 female cases) and 50,310 deaths
were estimated in the United States [2]. Local recurrence
and distant metastasis are major treatment failures of rec-
tal cancer. In the last few decades, improvements in surgi-
cal techniques such as total mesorectal excision (TME)
have reduced the local recurrence rates to <8 % [3–5]. In
Western countries, the addition of (neo) adjuvant therapy
has led to improvements in post-TME local control [6].
Based on current evidence, the gold standard for the treat-
ment of stages II and III rectal cancer includes neoadju-
vant chemoradiotherapy (CRT) before TME followed by
postoperative chemotherapy [7, 8].
Although studies have confirmed that preoperative
5-fluorouracil (5-FU)-based CRT can reduce the local re-
currence rate in colorectal cancer [6, 9], distant metastasis
remains uncontrolled. The challenge is to integrate a new
active agent to enhance the systemic control efficacy of
neoadjuvant treatment. When combined with 5-FU, oxali-
platin has been shown to increase the tumor response in
cases of metastatic colorectal cancer [10] and to be a po-
tent radiosensitizing agent in preclinical studies [11, 12].
Furthermore, a recent meta-analysis suggests that the
addition of oxaliplatin might improve the pathologic
complete response (pCR) rate and reduce the periopera-
tive metastatic rate [13].
However, the benefit of the addition of neoadjuvant
CRT to surgery as compared with surgery without neo-
adjuvant CRT should be analyzed in terms of local con-
trol, toxicity, survival, and quality of life. The adverse
effects of CRT, which include fecal incontinence, sexual,
urinary, and bowel dysfunction, and secondary malig-
nancy, can impair the quality of life of the patients and
reduce life expectancy [14–16]. Furthermore, unneces-
sary neoadjuvant treatment gives great financial burden
for patients. On the other hand, TME is a difficult sur-
gery, and well-performed surgery has been shown to be
a major short- and long-term prognostic factor of rectal
cancer. Increased body mass index (BMI) is associated
with a higher likelihood of local recurrence in patients
with rectal cancer [17, 18]. Chinese patients always have
a lower BMI compared with European patients, indicat-
ing better survival in the former group. Recent evidence
suggests that the overtreatment of patients with CRT
leads to unnecessary exposure to radiation and acute
and long-term toxicity of radiotherapy, and it remains
unclear whether TME without neoadjuvant CRT is ad-
equate in treating the vast majority of Chinese patients.
Therefore, in the present study, we compared the effi-
cacy of TME with versus without preoperative concur-
rent chemoradiotherapy (CCRT) with capecitabine plusoxaliplatin (XELOX) in Chinese patients with stage II
and III mid/low rectal adenocarcinoma.
Materials and methods
Study design
The present study was designed as a prospective, ran-
domized phase II trial. The primary endpoint was
disease-free survival (DFS); the secondary endpoints
were overall survival (OS), local and distant recurrence,
tumor response to CRT, toxicity, sphincter preservation,
and surgical complications. We hypothesized that the 3-
year DFS rate of patients who underwent either CCRT
followed by TME (the CCRT + TME group) or TME
without CCRT (the TME group) would be 80 %; a sam-
ple size of 252 patients per group achieved 80 % power
to detect a noninferiority margin difference of −10 % be-
tween the group proportions. The CCRT + TME group
proportion was assumed to be 70 % under the null hy-
pothesis of inferiority. The power was computed for a
case in which the actual study arm proportion was 80 %.
The test statistic used was the 1-sided z test (unpooled).
The significance level of the test was set at 0.025. An in-
terim analysis was designed when the first group of 180
patients had completed all therapies and was followed
up for at least 6 months.
Patient selection
The enrollment criteria were as follows: pathologically con-
firmed rectal adenocarcinoma within 10 cm from the anal
verge, the presence of clinical T3–T4 or node-positive re-
sectable tumor, no extension of the malignant disease to the
anal canal, and no evidence of distant metastasis. Tumor
stage was determined according to the 2002 American Joint
Committee on Cancer (AJCC) staging system. The staging
workup included colonofiberscopy, endorectal ultrasonog-
raphy (ERUS), chest computed tomography (CT), abdomi-
nopelvic CT, and/or abdominopelvic magnetic resonance
imaging (MRI). Rigid sigmoidoscopy was also performed
to determine the actual distance of the tumor from the
anal verge. Further inclusion criteria were a Karnofsky
Performance Scale score ≥70 points, age between 18 and
70 years, and adequate bone marrow function (hemoglobin
level ≥100 g/L, white blood cell count ≥3.5 × 109/L, abso-
lute neutrophil count ≥1.5 × 109/L, platelet count ≥100 ×
109/L), renal function (creatinine ≤1.5 × the upper limit of
the normal range [ULN]), and hepatic function (aspartate ami-
notransferase/alanine aminotransferase [AST/ALT] ≤2.5 ×
ULN, alkaline phosphatase ≤2.5 × ULN).
The exclusion criteria included previously administered
pelvic radiotherapy or chemotherapy, inflammatory bowel
disease, malabsorption syndrome, a history of other can-
cers, cardiac arrhythmia, coronary heart disease, peripheral
neuropathy, and psychiatric disorders or psychologic dis-
abilities that might adversely affect treatment compliance.
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ing potential who lacked effective contraception were
also excluded.
Ethics
The Sun Yat-sen University Cancer Center Institutional
Review Board on Medical Ethics approved this study,
and we performed the study in accordance with the Dec-
laration of Helsinki. All patients provided written in-
formed consent.
Randomization and treatment
Patients were randomly allocated (1:1) by a computer-
generated scheme, and their identities were concealed in
sequentially numbered, opaque, sealed envelopes; the
patients were then divided into the TME and CCRT +
TME groups.
Radiotherapy
Three-dimensional (3D) conformal radiotherapy was
planned with the Pinnacle 8 treatment planning system
(Philips, Amsterdam, Netherlands) using a 3-field irradi-
ation technique with 8-MV X-rays. The gross tumor vol-
ume (GTV) was defined as all known gross lesions,
including abnormally enlarged regional lymph nodes.
The clinical target volume (CTV) included primary rec-
tal tumor lesions, the two end portions of the rectum,
perirectal tissues, and anterior sacral, iliac, obturator,
and true pelvic internal iliac lymph drainage areas. In
patients with T4 lesions or bladder-invading tumors, the
CTV also included the external iliac lymph drainage
area. The planned target volume (PTV) was defined as
the CTV or GTV with 8-mm margin extension. Before
2011, a total dose of 46 Gy was delivered to the CTV in
23 fractions of 2 Gy each without a boost dose. From
2011 onwards, an addition of a 4-Gy boost dose that in-
volved 2 fractions of 2 Gy each to the GTV increased
the total dose to 50 Gy.
Chemotherapy
Patients in the CCRT +TME group received 2 cycles of a
modified XELOX regimen (oxaliplatin at 100 mg/m2 on
Day 1 and capecitabine at 1,000 mg/m2 twice daily on
Days 1–14 with an interval of 7 days) before TME,4 cycles
of standard XELOX regimen (oxaliplatin at 130 mg/m2 on
Day 1 and capecitabine at 1,000 mg/m2 twice daily on
Days 1–14 with an interval of 7 days), and 2 cycles of
capecitabine (1,000 mg/m2 twice daily on Days 1–14 with
an interval of 7 days) after TME. In the TME group, pa-
tients with postoperative pathologic stages II–III disease
were recommended to receive 6 cycles of standard
XELOX regimen. All patients received standard anti-
emetic prophylaxis that consisted of 5-hydroxytryptamine
receptor 3 (5-HT3R) antagonists and dexamethasone.Surgery
Patients underwent TME according to a standardized tech-
nique within 6–10 weeks after the completion of CRT. The
surgeon made decisions regarding a covering stoma during
the surgery. When the completeness of the TME was
doubted, a frozen section of the mesorectal margin was
subjected to intraoperative pathologic examination.
Histopathologic assessment of the response to CRT
All patients underwent a diagnostic tumor biopsy before
treatment. Sections with 4-mm thickness were obtained
from a representative formalin-fixed, paraffin-embedded
tumor tissue block. Pathologic evaluation of surgically
resected specimens included tumor–node–metastasis
(TNM) categorization, stage grouping, numbers of exam-
ined and involved lymph nodes, and tumor differentiation.
A pathologic complete response (pCR) was defined as the
complete disappearance of tumor cells. Primary tumor
regression was semiquantitatively determined by the
amount of viable tumor vs. the amount of fibrosis, which
ranged from no evidence of treatment effect to complete
response (CR) with no viable tumor identified, according
to the Dworak regression grading system, as follows [19]:
0 (no regression), 1 (dominant tumor with fibrosis in 25 %
of the tumor mass), 2 (dominant tumor with fibrosis in
26 %–50 % of the tumor mass), 3 (>50 % tumor regres-
sion), and 4 (complete regression).
Toxicity evaluation and intervention
The patient’s medical history, clinical examination results,
blood counts, and biochemistry results, including liver
function, were monitored weekly. We used the National
Cancer Institute Common Toxicity Criteria (NCI-CTC)
version 3.0 to grade the toxicity. If an adverse effect > grade
2 (hematologic or gastrointestinal) was determined to be
primarily chemotherapy-related, chemotherapy was discon-
tinued until the toxicity resolved to grade 0–1. Capecitabine
and oxaliplatin doses were adjusted for adverse events ac-
cording to a previously described standard procedure [20].
If an adverse effect > grade 2 (hematologic or gastrointes-
tinal) was determined to be primarily radiotherapy-related,
radiotherapy was discontinued until the toxicity resolved to
grade 0–1.
Follow-up
The follow-up protocol included evaluations every
3 months for the first 2 years after the completion of all
treatments and every 6 months thereafter. Evaluations at
each visit included complete blood count, liver function
test, carcinoembryonic antigen (CEA) and cancer antigen
19–9 (CA19-9) measurements, and physical examination.
Chest, abdominal, pelvic CT, pelvic endoscopic ultrason-
ography, and/or MRI were conducted every 6 months









Male 51 (54.3) 56 (62.2)
Female 43 (45.7) 34 (37.8)
Distance from the lower tumor margin to the anal verge 1.119 0.290
≤5 cm 47 (50.0) 52 (57.8)
>5-10 cm 47 (50.0) 38 (42.2)
T stage 6.833 0.033
cT2 8 (8.5) 2 (2.2)
cT3 69 (73.4) 60 (66.7)
cT4 17 (18.1) 28 (31.1)
N stage 3.305 0.069
cN0 48 (51.1) 33 (36.7)
cN+ 46 (48.9) 57 (63.3)
Clinical stage 2.752 0.097
II 48 (51.1) 33 (36.7)
III 46 (48.9) 57 (63.3)
TME, total mesorectal excision; CCRT, concurrent chemoradiotherapy
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database. The cutoff date for this trial was April 15, 2014.
Statistical analyses
>Survival curves were constructed using the Kaplan–Meier
method and compared using the log-rank test. The pre-
treatment characteristics were compared using the Pearson
chi-square test and the independent sample t-test. A Cox
regression model was used for the multivariate analysis. All
P values were 2-tailed and were considered significant
when <0.05. Statistical analyses were performed with SPSS
13 for Windows (SPSS, Inc., Chicago, IL, USA).
Results
Clinicopathologic characteristics
Trial recruitment began on March 23, 2008, and ended
on August 2, 2012, after we had enrolled 192 patients
from a single institution. Of these 192 patients, 95
underwent surgery without preoperative CCRT (the
TME group), and 97 underwent preoperative CCRT and
surgery (the CCRT + TME group). Eight patients (4.2 %)
were ineligible: in the TME group, distant metastasis
was found in 1 patient during surgery; in the CCRT +
TME group, distant metastasis was found in 3 patients
during surgery, and 4 rejected surgery after preoperative
CCRT. Forty-eight patients did not receive adjuvant
chemotherapy because of refusal or unsuitability. The me-
dian age was 58 (range, 29–70) in the TME group and 56
(range, 28–70) in the CCRT + TME group (P = 0.219).
Table 1 lists the baseline patient characteristics. The
demographic and treatment characteristics of the two
groups were comparable.
Chemotherapy dose and compliance
Patients received a total of 1,007 capecitabine-based
chemotherapy cycles. The CCRT + TME group received
2 cycles (total, 180 cycles) of capecitabine-based chemo-
therapy before TME and a median of 5 (range, 0–6;
total, 396) cycles of capecitabine-based chemotherapy;
the TME group received a median of 6 (range, 0–8; total,
431) cycles of capecitabine-based chemotherapy. All
chemotherapy cycles were completed in both groups.
Tumor response to CRT in the CCRT + TME group
The pCR rate in the CCRT +TME group was 35.6 % (32/
90). Nodal status down-staging (cN+ to post-treatment
pN0) was detected in 43 (75.4 %) of 57 patients, and the T
category was down-staged in 68 (75.6 %) of 90 patients
(Table 2). In all, 36 (40.0 %) patients exhibited grade 2 or
3 tumor regression.
CCRT safety and dose intensity
All patients were able to be evaluated for toxicity. No
treatment-related deaths occurred, and no patient developedgrade 4 toxicity. Table 3 lists the adverse events that were
observed during CCRT. Diarrhea was the most commonly
observed event; 10 patients (11.1 %) developed grade 3
diarrhea. All grade 3 diarrhea events lasted less than 72 h
because of adequate treatment with loperamide and oral
fluid intake. No patient developed renal failure because of
diarrhea. The hematologic toxicity was mild, and only 3
patients developed grade 3 leukocytopenia. No neutro-
penic fever was reported, and no patient received prophy-
lactic or therapeutic granulocyte colony-stimulating factor
during CCRT. Only 3 patients developed grade 1 anemia.
Prophylactic recombinant human erythropoietin was not
given, and no blood transfusions were required during
CCRT. Grades 1–2 AST/ALT elevation, which was ob-
served in 8 patients, might have been a consequence of
the chemotherapy. Radiotherapy was administered, as pre-
scribed, to all patients: 71 (78.9 %) received 46 Gy via 3D
conformal radiotherapy, and 19 (21.1 %) received 50 Gy
via intensity-modulated radiotherapy.
Resectability and sphincter preservation
R0 resection was achieved in all patients. Furthermore,
16 (17.0 %) patients in the TME group were shown to
have pTNM stage I disease after surgery. The staging
accuracy in the TME group was 62.8 % (59/94) for T cat-
egory (16 [17.0 %] up-staged and 19 [20.2 %] down-
staged) and 41.5 % (39/94) for N category (28 [29.8 %]
Table 2 Pathologic stage of the 90 patients in the CCRT + TME group (cases)
Baseline stage ypT0 ypT1 ypT2 ypT3 ypT4 Total Baseline stage ypN0 ypN1 ypN2 Total
T2 2 0 0 0 0 2 N- 27 6 0 33
T3 25 1 15 18 1 60 N+ 43 12 2 57
T4 7 1 5 12 3 28 - - - - -
Total 34 2 20 30 4 90 Total 70 18 2 90
yp, pathologic stage after CCRT
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functional sphincter preservation rate was 70.7 % (130/
184). The functional sphincter preservation rates were
71.3 % (67/94) in the TME group and 70 % (63/90) in
the CCRT + TME group (P = 0.849). The proportions of
patients with tumors within 5 cm from the anal verge
were similar in the CCRT + TME and TME groups
(57.8 % vs. 50.0 %, P = 0.290).Surgical complications
Table 4 lists the surgical parameters and complications.
No postoperative deaths occurred in either group. The
rates of anastomotic leakage were 8.5 % in the TME
group and 2.2 % in the CCRT + TME group (P = 0.101).
The rates of genitourinary symptoms, obstruction,
colostomy, and wound infections were also similar in
both groups.Table 3 Adverse events during CCRT for the 90 patients in the
CCRT + TME group (cases)
Adverse event NCI-CTC grade
0 1 2 3 4
Hematologic toxicity
Anemia 87 3 0 0 0
Thrombocytopenia 84 5 1 0 0
Leukocytopenia 74 5 8 3 0
Non-hematologic toxicity
Diarrhea 50 16 14 10 0
Nausea/vomiting 62 18 10 0 0
Stomatitis 80 10 0 0 0
Abdominal pain 78 8 4 0 0
Proctitis 58 16 16 0 0
Metabolic/laboratory abnormality
AST/ALT elevation 82 6 2 0 0
Bilirubin elevation 86 3 1 0 0
Creatinine elevation 89 1 0 0 0
Radiation-related toxicity
Hand-foot skin reaction 73 13 4 0 0
Dermatitis 66 16 8 0 0
AST, aspirate aminotransferase; ALT, alanine aminotransferase; NCI-CTC,
National Cancer Institute Common Toxicity CriteriaTumor control and survival
At the time of the analysis (April 2014), the median
follow-up period was 38 (range, 4–68) months for all pa-
tients, 43 (range, 4–67) months for the CCRT + TME
group, and 43.5 (range, 6–68) months for the TME
group (P = 0.825). The 3-year DFS and OS rates were
86.3 % and 91.5 %, respectively, in the whole cohort. No
significant differences in DFS and OS were found be-
tween the two groups (Table 5). Fig. 1 depicts the sur-
vival curves of patients in the TME and CCRT + TME
groups. In the TME group, 2 patients developed local re-
currence, 10 developed distant metastasis, and 2 devel-
oped both local recurrence and distant metastasis; in the
CCRT +TME group, 1 patient developed local recurrence,
6 developed distant metastasis, and 3 developed both local
recurrence and distant metastasis (Fig. 2, Table 5).Discussion
This trial failed to show differences in DFS, OS, and
local recurrence between the TME and CCRT + TME
groups. The cumulative incidences of local recurrence
were only 4.3 % in the TME group and 4.4 % in the
CCRT + TME group. The 3-year DFS rates were 85.7 %
in the TME group and 87.9 % in the CCRT + TME
group (P = 0.766); the 3-year OS rates were 90.7 % and
92.3 % (P = 0.855), respectively. The sphincter preserva-
tion rates in our study (70.7 %) were similar to those re-
ported in previous phase III studies (60 %–75 %) [21, 22].
Moreover, we detected nodal status and T category down-
staging in 75.4 % and 75.6 % of patients, respectively.
Several possible reasons might explain the similar results
obtained in both groups.
Incorrect preoperative staging may affect treatment
decision, even leading to overtreatment. In our study,
most patients (83.2 %) underwent abdominopelvic CT
for staging. The staging accuracy in the TME group was
62.8 % for T stage (17.0 % up-staged and 20.2% down-
staged) and 41.5 % for N stage (29.8 % up-staged and
28.7 % down-staged). Sixteen (17.0%) patients in the
TME group were proven to have pTNM stage I disease
after surgery. We believe that the CCRT + TME group
would contain a similar percentage of patients with
pTNM stage I disease and that these patients would not
benefit from preoperative CCRT. Therefore, preoperative
Table 4 Surgical parameters and tumor regression after treatment in the TME and CCRT + TME groups
Variable TME group CCRT + TME group χ2 P
Total (cases) 94 90
Sphincter preservation (cases [%]) 0.036 0.849
Yes 67 (71.3) 63 (70.0)
No 27 (28.7) 27 (30.0)
Time of surgery (hours) −1.106 0.269
Median 3 3
Range 2-6 2-10
Blood loss during surgery (mL) −0.387 0.698
Median 100 100
Range 20-1,000 50-1,000




Urinary symptoms 0 2 (2.2) 0.238
Anastomotic leakage 8 (8.5) 2 (2.2) 0.101
Obstruction 1 (1.1) 1 (1.1) 1.000
Temporary colostomy 0 3 (3.3) 0.115
Wound infection 4 (4.3) 4 (4.4) 1.000
Tumor regression gradea (cases [%])
4 NA 34 (37.8)
3 NA 23 (25.6)
2 NA 13 (14.4)
1 NA 20 (22.2)
pTNM stage (cases [%]) 3.202 0.202
T1-2N0M0 16 (17.0) 17 (18.9)
T3-4N0M0 39 (41.5) 21 (23.3)
T1-4 N1-2 M0 39 (41.5) 20 (22.2)
pCR (cases [%]) NA 32 (35.6)
pCR, pathologic complete response (ypT0N0); NA, not applicable. Other abbreviations as in Table 1. aThe Dworak regression grading system was used for tumor
regression grading
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that lead to similarities between the groups.
Currently, new techniques such as MRI or positron
emission tomography (PET) are used to improve the ac-
curacy of lymph node staging [23, 24]. High-resolution
MRI can more accurately and reproducibly predict theTable 5 Tumor control and survival of the patients in the TME
and CCRT + TME groups







TME 85.7 90.7 4 (4.3) 12 (12.8)
CCRT + TME 87.9 92.3 4 (4.4) 9 (10.0)
P 0.766 0.855 0.776 0.834tumor stages of rectal cancer [25]. Fluorodeoxyglucose
(FDG) PET/CT appears to be less accurate than MRI for
lymph node staging which is due to its inability to detect
lymph node micrometastases (<5 mm) and the “blooming
effect” of primary hot lesions that overshadow the nearest
lymph nodes [26]. Nevertheless, several studies have re-
ported a higher specificity of FDG PET/CT compared with
MRI (83 %–85 % vs. 67 %) in terms of nodal staging, sug-
gesting that in cases of rectal cancer, a glucose-avid lymph
node is most likely positive [27, 28]. Based on these find-
ings, PET/CT provides additional benefits for the discrim-
ination of metastatic lymph nodes in patients with rectal
cancer. Additionally, combined MRI and PET (fusion im-
aging) will be expected to increase the accuracy of nodal
staging predictions.
Fig. 1 Kaplan-Meier survival curves of the patients with mid/low rectal cancer in the TME and CCRT + TME groups. TME, total mesorectal excision;
CCRT, concurrent chemoradiotherapy; HR, hazard ratio; CI, confidence interval. a, the overall survival (OS) curve of the whole cohort. b, the
disease-free survival (DFS) curve of the whole cohort. c, the OS curves of the TME and CCRT + TME groups. d, the DFS curves of the TME and
CCRT + TME groups.
Fig. 2 Kaplan-Meier curves of local recurrence and distant metastasis in the TME and CCRT + TME groups. a, local recurrence rates were similar in
the TME and CCRT + TME groups. b, distant metastasis rates were similar in the TME and CCRT + TME groups.
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the two groups in our study might be the BMI of these
Chinese patients. TME is a difficult surgery, and the
quality of the surgery may be influenced by several fac-
tors such as a narrow pelvic diameter on MRI and
pathologic BMI (either above or below the normal
range). A high BMI has been associated with technical
difficulty in the surgical procedure and increased peri-
operative complications, which may result in an in-
creased risk of local recurrence in patients with rectal
cancer [17, 18]. Chinese patients might therefore benefit
from a lower BMI as compared with patients from
Western countries. In our study, all patients had R0 re-
section compared with 96.8 % of European and Canadian
patients [29]. Consequently, neoadjuvant CRT may not be
as vital for some Chinese patients. Furthermore, the small
sample sizes and the relatively short follow-up periods of
previous trials might have limited the ability to detect
moderate but clinically important differences.
The most likely explanation for the similarities between
the two groups in our study is that oxaliplatin may not be
a clinically effective radiation sensitizer. Based on its suc-
cessful use in colorectal cancer, oxaliplatin was used in
combination with radiation, and existing preclinical data
demonstrated the synergistic effects of oxaliplatin and ra-
diation [30–32]. Furthermore, early clinical trials reported
promising activity when oxaliplatin was added to 5-FU-
based CRT in patients with stages II–III rectal cancer
[11, 12, 19, 33]. However, data from phase III trials suggest
that oxaliplatin induces toxicity without conferring a clin-
ical benefit and therefore should not be included in stand-
ard preoperative CRT [22, 34]. Intriguingly, the pCR rate
of the CCRT + TME group in our study was higher than
the rates reported by several phase III clinical trials that
combined radiation and the XELOX regimen (35.6 % vs.
16 %–21 %) [35]. We also found that only 9 (10.0 %) pa-
tients in the CCRT +TME group developed distant me-
tastasis compared with 12 (12.8 %) in the TME group. The
pCR rate in our study (35.6 %) was also much higher than
those in phase II studies that used capecitabine and radio-
therapy as neoadjuvant treatments for locally advanced
rectal cancer, in which the reported pCR rates only ranged
from 7 % to 24 % [36]. The modified XELOX regimen
used in our trial apparently led to a higher pCR rate com-
pared with regimens that included weekly oxaliplatin.
Our trial suggests that CRT with capecitabine and oxali-
platin is well tolerated in patients with locally advanced
rectal cancer. No postoperative deaths occurred in either
group. The rates of urinary symptoms, obstruction, colos-
tomy, and wound infections were similar between the
groups, as were the duration of surgery, blood loss during
surgery, and the duration of hospital stay. The potential
adverse effects of various radiotherapy and chemotherapy
combinations are currently being investigated in patientswith locally advanced rectal cancer. In other countries,
phase III clinical trials of neoadjuvant 5-FU and oxalipla-
tin combined with radiation for patients with rectal cancer
have shown that the most frequently reported toxicity was
grade 3/4 diarrhea, with incidence ranging from 12 % to
15 % [23, 35]. This is in accordance with the results of our
study, where grade 3 diarrhea was the main toxicity, and
we observed no increase in postoperative morbidity.
Hematologic toxicity was mild. Therefore, the addition of
oxaliplatin to a preoperative capecitabine-based radiother-
apy regimen is safe and does not require dose reductions
of the treatment components.
Interestingly, recent studies have shown that for selected
patients with clinical stage II/III rectal cancer, neoadjuvant
chemotherapy without radiotherapy might also be effect-
ive [37, 38]. However, it shall be noted that selective treat-
ment strategies for these patients significantly rely on the
ability of the imaging techniques to allow for an accurate
identification of the stage of rectal tumors and the high-
risk features at baseline. Additionally, the actual applic-
ability of these results [37, 38] is limited by the sample
size, the exclusion of most patients with “ugly tumors”
(T4 tumors with overgrowth to the prostate, seminal vesi-
cles, base of urinary bladder, pelvic side walls or floor, and
sacrum; positive lateral lymph nodes; and positive circum-
ferential resection margin [CRM]) [39], the lack of a
control group treated with preoperative radiotherapy,
established risk-adapted criteria for patient selection, and
sufficient long-term follow-up.
Several limitations of the present study should be
mentioned. We have presented only an interim analysis
of the trial. The current sample size did not meet the
designated requirements, and longer follow-up is on-
going to determine the definite role of the CCRT + TME
strategy on local control and survival. In addition, the
staging accuracy in the TME group was only 62.8 % for
T stage and 41.5 % for N stage. New techniques such as
MRI, ERUS, and even PET/CT are needed to improve
the staging accuracy. Therefore, our results should be
interpreted with caution.
Conclusions
Preliminary results of the trial failed to show differences in
DFS, OS, and sphincter preservation rates between the
TME and CCRT+TME groups in Chinese patients. TME
without preoperative CCRT may be adequate in treating
the Chinese patients with stages II and III mid/low rectal
adenocarcinoma, although longer follow-up and further re-
search is needed to verify this finding. Adding oxaliplatin to
fluorouracil-based preoperative chemoradiotherapy signifi-
cantly increases short-term efficacy and can be safely com-
bined with capecitabine plus radiotherapy in Chinese
patients with rectal cancer. The long-term benefits are still
under observation.
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